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Table 2
Time from completion of treatment to conﬁrmation of relapse stratiﬁed by age
Age at primary diagnosis
<5 5-15 >15 Total (%)
Time from completion of treatment to diagnosis of relapse
<3 months 0 0 0 0 (0)
3-6 months 0 3 4 7 (8.8)
6-9 months 3 14 8 25 (31.3)
9-12 months 1 7 14 22 (27.5)15th ICID Abstracts / International Journ
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itra1, M.A. Lima3, P.P. Palma3
Medecins Sans Frontieres, Delhi, New Delhi, India
Rajindra Memorial Research Institute, Patna, India
Medecins Sans Frontieres, Barcelona, Spain
Background: India reportedly has 70% of theworldwide burden
f Visceral Leishmaniasis(VL), with Bihar having 90% of reported
ases. With the support of the RMRI, MSF has implemented a
L treatment project in Vaishali district, endemic for Leishmania
onovani, using total dose 20mg/Kg liposomal amphotericin-B(L-
mB) as the ﬁrst-line drug.
Methods: Intravenous L-AmB(Ambisome) has been adminis-
ered in four doses of 5mg/kg/doses to a total dose of 20mg/kg
o all patients identiﬁed as primary VL over a period of 5 to 10
ays depending on the severity of disease. All patients are routinely
iven comprehensive health education regardingVL and instructed
o return immediately if any recurrence of symptoms occurred. The
xcel based database of the project was analysed over a 4-year
eriod from September 2007-December 2011. All immunocompe-
ent patients readmitted with biopsy conﬁrmed VL who had been
reviously treated for primary VL within the programme were
dentiﬁed, described and compared to the parameters of overall
dmissions of immunocompetent patients with primary VL within
he same period.
Results: 6435 immunocompetent primary VL patients were
reated during the analysis period with 20mg/Kg LAmb. 80 of these
atients re-presented with parasite conﬁrmed relapses. This con-
tituted a minimum of 1.2% of the overall treated, however passive
able 1
omparison of relapse case parameters to baseline admissions
Relapse Baseline
Risk Factor N % N % RR 95% CI P-Value
Age
<5 7 8.8 428 6.7 1.34 (0.60-2.98) 0.47
5-15 33 41.3 2632 41.4 1.03 (0.65-1.63) 0.89
>15 40 50 3295 51.8 1
Gendet
M 59 73.8 3531 55.6 2.22 (1.36-3.66) 0.001
F 21 26.3 2824 44.4 1
Time from symptoms onset to diagnosis
≤2 weeks 24 30 918 14.4 1
2-4 weeks 34 42.5 2754 43.3 0.48 (0.2-0.80) 0.004
4-8 weeks 15 18.8 1632 25.7 0.36 (0.19-0.68) 0.001
8-12 weeks 4 5.0 669 10.5 0.25 (0.08-0.67) 0.003
>12 weeks 3 3.8 382 6.0 0.31 (0.09-1.01) 0.038
Hb (g/dl)
<6 10 13.7 840 13.2 0.98 (0.49-1.95) 0.96
6-8 22 30.1 2132 33.5 0.85 (0.31-1.42) 0.54
>8 41 56.2 3383 53.2 1
Spleen Size
<3 cm 13 17.8 995 15.7 1
3-6 cm 43 58.9 3279 51.6 1.004 (0.54-1.86) 0.99
<6 cm 17 23.3 2078 32.7 0.63 (0.31-1.29) 0.20
Nutritional Status
Severe Acute Malnutrition 12 19.4 956 18.9 1.13 (0.59-2.18) 0.72
Moderate Acute Malnutrition 17 27.4 1138 22.5 1.34 (0.75-2.40) 0.32
Normal Nutritional Status 33 53.2 2971 58.7 112-18 months 1 7 5 13 (16.3)
>18 months 2 2 9 13 (16.3)
Total 7 33 40 80
follow up may underestimate the real number.The parameters of
the relapse cases are compared to the baseline data from the overall
admissions in Table 1. Male sex and shorter time from symptoms
to diagnosis were associated with risk of VL relapse.The average
(SD) length of time following completion of initial treatment to
parasite conﬁrmation was 385 (272) days (range:104 -1626), with
59% occurring between 6 and 12 months (Table 2).Conclusion: To
our knowledge this is the only study of relapses in immunocom-
petent primary VL patients treated with L-AmB. Although passive
follow up limits interpretation, only male sex and short treatment
delay seem to be associated with risk of VL relapse. The majority
of relapses occurring between 6-12 months post treatment is of
interest and may suggest that a longer period of follow up could
be appropriate for patients treated with L-Amb in light of WHO
recommendations for 10mg single dose therapy.
http://dx.doi.org/10.1016/j.ijid.2012.05.346
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Invasion kinetics of human endothelial cells by Toxoplasma
gondii RH and ME49 strains
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Background: Toxoplasma gondii may cause congenital infec-
tion in the developing foetus. Invasion of endothelial cells lining
the placental blood vessels is supposed to be the main vertical
transmission route. Genotypic analysis of T. gondii isolates iden-
tiﬁed a population structure of 11 haplogroups, from which three
clonal lineages, type I, II, and III are well known. Although, type
II strains are more prevalent in Europe and North America, type
I strains are over-represented in congenital toxoplasmosis; also,
type I strains are highly virulent to mice and traverse epithelial
barriers more effectively than type II. The aim of this study was
to compare the invasion kinetics of T. gondii RH and ME49 strains
in human microvascular endothelial cells(HMEC-1) and umbilical
vein endothelial cells (HUVECs).
Methods: RH and ME49 Toxoplasma gondii strains were
expanded in Balb/c and C57BL6-RAG2 -/- mice, respecitvely. After
one replication cycle inVERO cell cultures (ﬁgure) tachyzoiteswere
seeded at 10:1 parasite:cell ratio in 24-well plates containing slides
withmonolayers of either HMEC-1 or HUVECs, at 100,000/well and
incubated for 30 min to 4h. The slides were ﬁxed and stained with
Wright to count percent of infected cells and number of parasitic
